{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:58:17Z","timestamp":1789001897868,"version":"build-2803163510"},"reference-count":78,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,6,5]],"date-time":"2018-06-05T00:00:00Z","timestamp":1528156800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Physiol."],"DOI":"10.3389\/fphys.2018.00692","type":"journal-article","created":{"date-parts":[[2018,6,5]],"date-time":"2018-06-05T04:29:16Z","timestamp":1528172956000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":56,"title":["Brain Natriuretic Peptide and Its Biochemical, Analytical, and Clinical Issues in Heart Failure: A Narrative Review"],"prefix":"10.3389","volume":"9","author":[{"given":"Shihui","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Ping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiwei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leiming","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,6,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1373\/clinchem.2004.044594","article-title":"Quality specifications for B-type natriuretic peptide assays.","volume":"51","author":"Apple","year":"2005","journal-title":"Clin. Chem."},{"key":"B2","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ejheart.2003.12.013","article-title":"N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction.","volume":"6","author":"Bayes-Genis","year":"2004","journal-title":"Eur. J. Heart Fail."},{"key":"B3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.cccn.2003.10.026","article-title":"The effect of classspecific protease inhibitors on the stabilization of B-type natriuretic peptide in human plasma.","volume":"340","author":"Belenky","year":"2004","journal-title":"Clin. Chim. Acta"},{"key":"B4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1373\/clinchem.2005.057638","article-title":"Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form.","volume":"52","author":"Brandt","year":"2006","journal-title":"Clin. Chem."},{"key":"B5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00109-011-0801-z","article-title":"Molecular mechanisms underlying cardiac antihypertrophic and antifibrotic effects of natriuretic peptides.","volume":"90","author":"Calvieri","year":"2012","journal-title":"J. Mol. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1073\/pnas.0407234102","article-title":"Hypertension in mice lacking the proatrial natriuretic peptide convertase corin.","volume":"102","author":"Chan","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/nm.3920","article-title":"PCSK6-mediated corin activation is essential for normal blood pressure.","volume":"21","author":"Chen","year":"2015","journal-title":"Nat. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1586\/14737159.2014.882772","article-title":"Heart failure biomarkers at point-of-care: current utilization and future potential.","volume":"14","author":"Christenson","year":"2014","journal-title":"Expert Rev. Mol. Diagn."},{"key":"B9","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3109\/10408363.2014.987720","article-title":"State of the art of immunoassay methods for B-type natriuretic peptides: an update.","volume":"52","author":"Clerico","year":"","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"H12","DOI":"10.1152\/ajpheart.00226.2011","article-title":"Thirty years of the heart as an endocrine organ: physiological role and clinical utility of cardiac natriuretic hormones.","volume":"301","author":"Clerico","year":"2011","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cca.2014.06.003","article-title":"Cardiac biomarker testing in the clinical laboratory: where do we stand? General overview of the methodology with special emphasis on natriuretic peptides.","volume":"443","author":"Clerico","year":"","journal-title":"Clin. Chim. Acta"},{"key":"B12","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1373\/clinchem.2004.038281","article-title":"Analytical performance and diagnostic accuracy of immunometric assays for the measurement of plasma BNP and NT-proBNP concentrations.","volume":"51","author":"Clerico","year":"2005","journal-title":"Clin. Chem."},{"key":"B13","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.cca.2012.07.017","article-title":"State of the art of BNP and NT-proBNP immunoassays: the CardioOrmoCheck study.","volume":"414","author":"Clerico","year":"2012","journal-title":"Clin. Chim. Acta"},{"key":"B14","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jchf.2013.03.001","article-title":"Secretion of prohormone of B-type natriuretic peptide, proBNP1-108, is increased in heart failure.","volume":"1","author":"Costello-Boerrigter","year":"2013","journal-title":"JACC Heart Fail."},{"key":"B15","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.phrs.2013.08.006","article-title":"Recent advances on natriuretic peptide system: new promising therapeutic targets for the treatment of heart failure.","volume":"76","author":"Del Ry","year":"2013","journal-title":"Pharmacol. Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.bcp.2010.06.015","article-title":"Human B-type natriuretic peptide is not degraded by meprin A.","volume":"80","author":"Dickey","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1373\/clinchem.2011.169151","article-title":"ProBNP1-108 is resistant to degradation and activates guanylyl cyclase-A with reduced potency.","volume":"57","author":"Dickey","year":"2011","journal-title":"Clin. Chem."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1093\/eurheartj\/ehn309","article-title":"ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM).","volume":"29","author":"Dickstein","year":"2008","journal-title":"Eur. Heart J."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1042\/CS20160398","article-title":"Localization of corin and atrial natriuretic peptide expression in human renal segments.","volume":"130","author":"Dong","year":"2016","journal-title":"Clin. Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.cca.2011.10.032","article-title":"Corin in clinical laboratory diagnostics.","volume":"413","author":"Dong","year":"2012","journal-title":"Clin. Chim. Acta"},{"key":"B21","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1161\/CIRCHEARTFAILURE.109.903153","article-title":"Simultaneous assessment of unprocessed ProBNP1-108 in addition to processed BNP32 improves identification of high-risk ambulatory patients with heart failure.","volume":"3","author":"Dries","year":"2010","journal-title":"Circ. Heart Fail."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1016\/j.jacc.2010.09.075","article-title":"Natriuretic peptide assays revisited: do we need pro-B-type natriuretic peptide?","volume":"57","author":"Emdin","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1042\/CS20120517","article-title":"Reduced urinary corin levels in patients with chronic kidney disease.","volume":"124","author":"Fang","year":"2013","journal-title":"Clin. Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1373\/clinchem.2012.200204","article-title":"Circulating fragments of N-terminal pro-B-type natriuretic peptides in plasma of heart failure patients.","volume":"59","author":"Foo","year":"2013","journal-title":"Clin. Chem."},{"key":"B25","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.cca.2013.07.001","article-title":"Systematic differences between BNP immunoassays: comparison of methods using standard protocols and quality control materials.","volume":"424","author":"Franzini","year":"2013","journal-title":"Clin. Chim. Acta"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1186\/s13036-017-0093-0","article-title":"Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure.","volume":"12","author":"Fu","year":"2018","journal-title":"J. Biol. Eng."},{"key":"B27","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3275\/8295","article-title":"Efficacy and safety of a modified dosage regimen of nesiritide in patients older than 75 years with acute heart failure.","volume":"24","author":"Fu","year":"2012","journal-title":"Aging Clin. Exp. Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.yjmcc.2007.10.002","article-title":"Corin is co-expressed with pro-ANP and localized on the cardiomyocyte surface in both zymogen and catalytically active forms.","volume":"44","author":"Gladysheva","year":"2008","journal-title":"J. Mol. Cell. Cardiol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1161\/HYPERTENSIONAHA.112.193631","article-title":"Corin overexpression improves cardiac function, heart failure, and survival in mice with dilated cardiomyopathy.","volume":"61","author":"Gladysheva","year":"2013","journal-title":"Hypertension"},{"key":"B30","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1093\/clinchem\/48.7.1035","article-title":"Quantification of pro-B-type natriuretic peptide and its products in human plasma by use of an analysis independent of precursor processing.","volume":"48","author":"Goetze","year":"2002","journal-title":"Clin. Chem."},{"key":"B31","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1373\/clinchem.2016.265397","article-title":"Unraveling the molecular complexity of O-glycosylated endogenous (N-Terminal) pro-B-type natriuretic peptide forms in blood plasma of patients with severe heart failure.","volume":"63","author":"Halfinger","year":"2017","journal-title":"Clin. Chem."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1161\/HYPERTENSIONAHA.106.081083","article-title":"Immunoreactivity and guanosine 3\u2032,5\u2032-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide.","volume":"49","author":"Heublein","year":"2007","journal-title":"Hypertension"},{"key":"B33","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1373\/clinchem.2010.153908","article-title":"Corin is present in the normal human heart, kidney, and blood, with pro-B-type natriuretic peptide processing in the circulation.","volume":"57","author":"Ichiki","year":"2011","journal-title":"Clin. Chem."},{"key":"B34","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1586\/14737159.2016.1158105","article-title":"Recent advances in point-of-care testing for natriuretic peptides: potential impact on heart failure diagnosis and management.","volume":"16","author":"Iwaz","year":"2016","journal-title":"Expert Rev. Mol. Diagn."},{"key":"B35","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1161\/CIRCULATIONAHA.112.120485","article-title":"Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are useful in heart failure management.","volume":"127","author":"Januzzi","year":"2013","journal-title":"Circulation"},{"key":"B36","doi-asserted-by":"publisher","first-page":"10066","DOI":"10.1074\/jbc.M110.185082","article-title":"Ectodomain shedding and autocleavage of the cardiac membrane protease corin.","volume":"286","author":"Jiang","year":"2011","journal-title":"J. Biol. Chem."},{"key":"B37","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2217\/bmm.12.67","article-title":"Equal performance of novel N-terminal proBNP (Cardiac proBNP) and established BNP (Triage BNP) point-of-care tests.","volume":"6","author":"Jungbauer","year":"2012","journal-title":"Biomark. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"12485","DOI":"10.1074\/jbc.M511083200","article-title":"Cell-surface processing of pro-ADAMTS9 by furin.","volume":"281","author":"Koo","year":"2006","journal-title":"J. Biol. Chem."},{"key":"B39","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jemermed.2005.10.001","article-title":"Impact of point-of-care Btype natriuretic peptide (BNP) measurement on medical decision-making for older emergency department patients with dyspnea.","volume":"31","author":"Kosowsky","year":"2006","journal-title":"J. Emerg. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1373\/clinchem.2016.269712","article-title":"Development of a BNP1-32 immunoassay that does not cross-react with proBNP.","volume":"63","author":"Lewis","year":"2017","journal-title":"Clin. Chem."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.jacc.2006.10.063","article-title":"Evidence for functional heterogeneity of circulating B-type natriuretic peptide.","volume":"49","author":"Liang","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1373\/clinchem.2007.097998","article-title":"Cross-reactivity of BNP, NT-proBNP, and proBNP in commercial BNP and NT-proBNP assays: preliminary observations from the IFCC Committee for standardization of markers of cardiac damage.","volume":"54","author":"Luckenbill","year":"2008","journal-title":"Clin. Chem."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.jacc.2011.01.005","article-title":"Pro-B-type natriuretic peptide 1-108 circulates in the general community: plasma determinants and detection of left ventricular systolic dysfunction.","volume":"57","author":"Macheret","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1016\/j.jacc.2013.01.052","article-title":"Primary results of the HABIT Trial (Heart failure assessment with BNP in the home).","volume":"61","author":"Maisel","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC.","volume":"33","author":"McMurray","year":"2012","journal-title":"Eur. Heart J."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1093\/eurjhf\/hft052","article-title":"Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure trial (PARADIGM-HF).","volume":"15","author":"McMurray","year":"2013","journal-title":"Eur. J. Heart Fail."},{"key":"B47","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure.","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1161\/CIRCHEARTFAILURE.110.960260","article-title":"Comparison of mass spectrometry and clinical assay measurements of circulating fragments of B-Type natriuretic peptide in patients with chronic heart failure.","volume":"4","author":"Miller","year":"2011","journal-title":"Circ. Heart Fail."},{"key":"B49","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.placenta.2016.10.002","article-title":"Increased levels of soluble corin in pre-eclampsia and fetal growth restriction.","volume":"48","author":"Miyazaki","year":"2016","journal-title":"Placenta"},{"key":"B50","doi-asserted-by":"publisher","first-page":"40","DOI":"10.7326\/M14-2957","article-title":"Effects of Proprotein convertase subtilisin\/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis.","volume":"163","author":"Navarese","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","article-title":"Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.","volume":"131","author":"Packer","year":"2015","journal-title":"Circulation"},{"key":"B52","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2147\/VHRM.S5789","article-title":"Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure.","volume":"6","author":"Palazzuoli","year":"2010","journal-title":"Vasc. Health Risk Manag."},{"key":"B53","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.jmb.2009.08.025","article-title":"Structural substrate conditions required for neutral endopeptidase-mediated natriuretic peptide degradation.","volume":"393","author":"Pankow","year":"2009","journal-title":"J. Mol. Biol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1373\/clinchem.2011.176990","article-title":"First identification of circulating prepro-A-type natriuretic peptide (preproANP) signal peptide fragments in humans: initial assessment as cardiovascular biomarkers.","volume":"58","author":"Pemberton","year":"2012","journal-title":"Clin. Chem."},{"key":"B55","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.bbrc.2011.06.192","article-title":"Glycosylation and processing of pro-B-type natriuretic peptide in cardiomyocytes.","volume":"411","author":"Peng","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B56","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1515\/cclm-2014-0873","article-title":"Comparison between BNP values measured in capillary blood samples with a POCT method and those measured in plasma venous samples with an automated platform.","volume":"53","author":"Prontera","year":"2015","journal-title":"Clin. Chem. Lab. Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"4670","DOI":"10.1074\/jbc.M110.173252","article-title":"Insulin-degrading enzyme modulates the natriuretic peptide-mediated signaling response.","volume":"286","author":"Ralat","year":"2011","journal-title":"J. Biol. Chem."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1373\/clinchem.2015.239673","article-title":"Influence of glycosylation on diagnostic and prognostic accuracy of N-terminal pro-B-type natriuretic peptide in acute dyspnea: data from the Akershus cardiac examination 2 study.","volume":"61","author":"Rosjo","year":"2015","journal-title":"Clin. Chem."},{"key":"B59","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1373\/clinchem.2016.263749","article-title":"Specificity of B-Type natriuretic peptide assays: cross-reactivity with different BNP, NT-proBNP, and proBNP Peptides.","volume":"63","author":"Saenger","year":"2017","journal-title":"Clin. Chem."},{"key":"B60","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1161\/CIRCHEARTFAILURE.113.000527","article-title":"Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.","volume":"7","author":"Sanders-van Wijk","year":"2014","journal-title":"Circ. Heart Fail."},{"key":"B61","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.abb.2006.03.028","article-title":"The precursor to B-type natriuretic peptide is an O-linked glycoprotein.","volume":"451","author":"Schellenberger","year":"2006","journal-title":"Arch. Biochem. Biophys."},{"key":"B62","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1373\/clinchem.2006.076141","article-title":"The brain natriuretic peptide (BNP) precursor is the major immunoreactive form of BNP in patients with heart failure.","volume":"53","author":"Seferian","year":"2007","journal-title":"Clin. Chem."},{"key":"B63","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1373\/clinchem.2007.100040","article-title":"Immunodetection of glycosylated NT-proBNP circulating in human blood.","volume":"54","author":"Seferian","year":"2008","journal-title":"Clin. Chem."},{"key":"B64","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1373\/clinchem.2016.254524","article-title":"Different susceptibility of B-Type natriuretic peptide (BNP) and BNP precursor (proBNP) to cleavage by neprilysin: the N-Terminal part does matter.","volume":"62","author":"Semenov","year":"2016","journal-title":"Clin. Chem."},{"key":"B65","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1373\/clinchem.2008.113373","article-title":"Processing of probrain natriuretic peptide is suppressed by O-glycosylation in the region close to the cleavage site.","volume":"55","author":"Semenov","year":"2009","journal-title":"Clin. Chem."},{"key":"B66","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1373\/clinchem.2010.161125","article-title":"Human pro-B-type natriuretic peptide is processed in the circulation in a rat model.","volume":"57","author":"Semenov","year":"2011","journal-title":"Clin. Chem."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1373\/clinchem.2010.143883","article-title":"Processing of pro-Btype natriuretic peptide: furin and corin as candidate convertases.","volume":"56","author":"Semenov","year":"2010","journal-title":"Clin. Chem."},{"key":"B68","first-page":"44","article-title":"Comparability of results between point-of-care and automated instruments to measure B-type natriuretic peptide.","volume":"11","author":"Shah","year":"2010","journal-title":"West. J. Emerg. Med."},{"key":"B69","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1373\/clinchem.2016.265140","article-title":"Prognostic role of molecular forms of B-Type natriuretic peptide in acute heart failure.","volume":"63","author":"Suzuki","year":"2017","journal-title":"Clin. Chem."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1373\/clinchem.2007.100545","article-title":"Novel immunoassay for quantification of brain natriuretic peptide and its precursor in human blood.","volume":"54","author":"Tamm","year":"2008","journal-title":"Clin. Chem."},{"key":"B71","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1093\/eurheartj\/ehq509","article-title":"Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care.","volume":"33","author":"Thygesen","year":"2012","journal-title":"Eur. Heart J."},{"key":"B72","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2174\/1389202911314050010","article-title":"Genetics of the first seven proprotein convertase enzymes in health and disease.","volume":"14","author":"Turpeinen","year":"2013","journal-title":"Curr. Genomics"},{"key":"B73","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s10741-011-9244-4","article-title":"Optimizing fluid management in patients with acute decompensated heart failure (ADHF): the emerging role of combined measurement of body hydration status and brain natriuretic peptide (BNP) levels.","volume":"16","author":"Valle","year":"2011","journal-title":"Heart Fail. Rev."},{"key":"B74","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1373\/clinchem.2016.254714","article-title":"Natriuretic peptides and analytical barriers.","volume":"63","author":"Vasile","year":"2017","journal-title":"Clin. Chem."},{"key":"B75","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.1093\/eurheartj\/ehu314","article-title":"Post-translational modifications enhance NT-proBNP and BNP production in acute decompensated heart failure.","volume":"35","author":"Vodovar","year":"2014","journal-title":"Eur. Heart J."},{"key":"B76","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/ejhf.468","article-title":"Natriuretic peptides and volume handling in heart failure: the paradigm of a new treatment.","volume":"18","author":"Volpe","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"B77","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1161\/CIRCRESAHA.115.307875","article-title":"Novel insights into the mechanisms regulating pro-atrial natriuretic peptide cleavage in the heart and blood pressure regulation: proprotein convertase subtilisin\/kexin 6 is the corin activating enzyme.","volume":"118","author":"Volpe","year":"2016","journal-title":"Circ. Res."},{"key":"B78","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1161\/CIRCRESAHA.108.177352","article-title":"Corin variant associated with hypertension and cardiac hypertrophy exhibits impaired zymogen activation and natriuretic peptide processing activity.","volume":"103","author":"Wang","year":"2008","journal-title":"Circ. Res."}],"container-title":["Frontiers in Physiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphys.2018.00692\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T03:22:30Z","timestamp":1604373750000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphys.2018.00692\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,5]]},"references-count":78,"alternative-id":["10.3389\/fphys.2018.00692"],"URL":"https:\/\/doi.org\/10.3389\/fphys.2018.00692","relation":{},"ISSN":["1664-042X"],"issn-type":[{"value":"1664-042X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,5]]},"article-number":"692"}}